We investigated whether 2-chlorodexoyadenosine could most cells are in the resting phase. 6, 7 In vitro studies have excellently with the classical DNA fragmentation assays.
Thus, we investigated whether 2-CdA could induce apoptosis in B-CLL cells in vitro using clinically achievable drug doses, measuring apoptosis ratio by flow cytometry. Introduction B cell chronic lymphocytic leukemia (B-CLL) is the most common form of leukemia in the Western world. B-CLL is characMaterials and methods terized by the slow and progressive accumulation of monoclonal, apparently mature, CD5 + B lymphocytes.
1,2
The Patients majority of circulating cells appears to be nondividing and it has been suggested that a prolonged life span is mainly responsible for the accumulation of the leukemic cells. HowTwenty-one patients with chronic lymphocytic leukemia were ever, spontaneous programmed death by apoptosis appears entered on this study, nine were male and 12 female. The when B-CLL cells were cultured in vitro. 3 median age was 70 years with a range of 31-89 years. Five The initial management of this disorder is not complicated of them had received chemotherapy for at least 4 months since a high proportion of patients have an asymptomatic before the samples were drawn and the other 16 patients were disease with slow progression, and those with symptomatic previously untreated. Diagnosis of B-CLL was unequivocal disease often respond (up to 60% of cases) to low doses of oral according to clinical, morphologic and immunological crialkylating agents and steroids.
2 However, the disease remains teria. The patients were classified according to Rai et al 14, 15 incurable, since resistance to alkylating agents frequently in stages 0-IV: seven patients were at clinical stage Rai 0, four develops. The vast majority of patients have a reduced life at Rai I, eight at Rai II and two at Rai IV (Table 1) . expectancy because of their leukemia. Recently, purine analogues such as 2-chlorodeoxyadenosine (2-CdA) and fludarabine have been synthesized, which have chemotherapeutic activity in refractory or untreated B-CLL. 4 Cell separation 2-Chlorodeoxyadenosine is a deoxyadenosine analog, consisting of substitution of a chlorine atom at the 2-position of the purine ring. 5 It is unique compared with traditional antiPeripheral blood mononuclear cells (PBMC) were obtained metabolite drugs in that it is equally active against dividing from sterile heparinized venous blood from patients by differand resting lymphocytes which may be especially important ential centrifugation on Ficoll-Hypaque (Lymphoprep; Nyein indolent lymphoid malignancies such as B-CLL, because gard, Oslo, Norway). B cells were isolated after rosetting out T cells with 2-aminoethylisothiouronium bromide-treated sheep red blood cells. This procedure gave a population of T celldepleted B-CLL cells containing less than 2% T cells and with (Table 2 and without 2-chlorodeoxyadenosine (Leustatin; Ortho Biotech, Raritan, NJ, USA) for 24 and 48 h, at the final concentrations Figure 1 ). 2-CdA-treated cells were incubated for 24 and 48 h with of 1.75 × 10 −6 M, 1.75 × 10 −7 M and 1.75 × 10 −8 M (500, 50 and 5 ng/ml, respectively) in a fully humidified atmosphere of three different levels of drug ( Table 2 ). The percentage of apoptotic cells after 24 h cultured with the lowest 2-CdA level 5% CO 2 at 37°C. For in vivo treatment each patient received 0.12 mg/kg daily as 2-h intravenous infusions for 5 consecu-(1.75 × 10 −8 M) was similar to the spontaneous apoptosis percentage shown in untreated cells (16.0 ± 10.3). Apoptotic cell tive days (0.6 mg/kg total). 16 The mean end of infusion plasma 2-CdA concentration is 48 ± 19 ng/ml, that is 1.75 × 10 −7 M in numbers were increased when drug concentration in culture was 1.75 × 10 −7 M, with 19.2 ± 21.5% of apoptotic cells in the our in vitro assay. 17 first 24 h. Moreover, leukemic lymphocytes treated with 1.75 × 10 −6 M 2-CdA showed apoptosis levels over 24.7 ± 11.1% after the first day of culture. These data have no Analysis of apoptosis statistical significance (Table 2 and Figure 1 ).
When cells were incubated for 48 h with 2-CdA Apoptosis was measured by flow cytometry and the level of DNA fragmentation. The distribution of cellular DNA content (1.75 × 10 −8 M), there were no differences with respect to the apoptosis shown in untreated cells culture (22.3 ± 19.1%). was determined by standard propidium iodide staining and flow cytometry using a FACScan flow cytometer with argon However, a significant increase of apoptosis was observed with respect to the basal (P = 0.014) when the 2-CdA level in laser excitation at 488 nm (Becton Dickinson, San José, CA, USA).
the culture was 1.7 × 10 −7 M. After 48 h we obtained an apoptotic cell ratio about 3.7 ± 6.6 higher than the spontaneous The 200 g centrifugated cell pellet was resuspended in 70% ethanol and placed on ice for 15 min. The cells were centrione. The highest drug dose (1.75 × 10 −6 M) produced an elevated percentage of apoptotic cells 55.1 ± 26.0% by 48 h. The fuged, washed in PBS and resuspended in 0.5 ml PBS containing propidium iodide (5 g/ml) and RNAse (50 mg/ml). Tubes last results are significant with respect to the basal (P = 0.000) and the ratio between apoptosis by 1.75 × 10 −6 M 2-CdA and were incubated in the dark at 4°C for 30 min prior to flow cytometry analysis. The staining was stable for at least 24 h spontaneous cell death is about 5.0 ± 6.6 (Table 2 and Figure 1 ). All these data demonstrate that apoptosis was dosewhen cells were kept refrigerated. 12 Flow cytometric apoptosis quantification was made with dependent, and occurred after 48 h in cultured cells. DNA fragmentation assay was shown in Figure 2 . 'Lysys II' and 'Paint-a-gate' analysis software. Necrotic cells, nuclear fragments or cell debris, with minimal DNA content, Incubation of lymphocytes with 2-CdA obtained from patients with Rai stage 0 or I disease in comparison to more were easily distinguishable from apoptotic cells and were excluded from the analysis to avoid overestimation of apopadvanced disease did not show significant differences in druginduced apoptosis (data not shown). Pronounced interpatient totic cell quantification. We used a two parameter dot-plot of a fluorescence peak width vs fluorescence peak area signals to gate out cell aggregates (doublets, triplets, etc) and necrotic escence of apoptotic cells. variation was evident in spontaneous and drug-induced taneous rate of cell death. 3, 19 One assumes this arises because of the lack of an unidentified essential cytokine. 20 Thus, apoptosis (Table 2) . apoptosis was observed during culture in the absence of drug in most cases. In contrast to drug-induced apoptosis, the degree of spontaneous cell death was lower and seemed to Discussion increase on prolongation of incubation. The diagnosis of CLL is not consonant with the need for The aim of the present study was to investigate the induction of apoptosis in human neoplastic B cells using 2-chlorodeoxytherapy. 21 Patients with early stage disease are usually not treated unless symptoms develop or disease progresses, and adenosine. In fact, in vitro exposure of CLL lymphocytes to 2-CdA triggered cell death characteristic apoptosis as we have have a low median survival. Patients with advanced disease have a much shorter survival. Chlorambucil should be still shown by flow cytometry. Flow cytometric analysis of cells after propidium iodide staining is widely utilized for evaluatconsidered the standard treatment. 22, 23 Response rates range from 40 to 70%, but complete responses are rare. For patients ing cell death, determining ploidy in tumor samples and measuring cell cycle parameters of cultured cells. 18 The apoptotic with no response to standard therapy or a relapse after such therapy, purine analogues (2′-deoxycoformycin, fludarabine cells are identified as an unequivocal hypodiploid DNA peak in the red fluorescence channels as a result of the reduced and 2-chlorodeoxyadenosine) are the treatment of choice.
24
2′-Deoxycoformycin is a potent inhibitor of adenosine deami-DNA content of apoptotic cells. 11 This method permits simple, quantitative and reproducible measurement of apoptosis. 12 nase. 25 Fludarabine is approved for the treatment of patients with chronic lymphocytic leukemia who are refractory to Chronic lymphocytic leukemia does not result directly from enhanced proliferation, but rather is caused by the progressive alkylating agents, 26 and 2-CdA for patients with untreated or interferon-refractory hairy cell leukemia. The effectiveness of accumulation of long-lived lymphocytes with enhanced viability. Paradoxically, short-term culture renders many of single-agent 2-CdA in patients with CLL who fail to respond to alkylator therapy was first reported in 1988. 27 In subsequent these cells susceptible to apoptosis. 3 Increasing the cell density or changing the source of serum did not affect this sponstudies high complete remission rates were obtained with 2- ND, not done. *P = 0.000; **P = 0.014.
complex but include the induction of apoptosis. 5, 8 Recent studies have demonstrated that programmed cell death by apoptosis is the mechanism of action of the most common treatment for CLL: the alkylating agent chlorambucil. 38, 39 2-Chlorodeoxyadenosine is unique compared with traditional antimetabolite drugs in that it is equally active against dividing and resting lymphocytes 6, 7 which may be especially important in indolent lymphoid malignancies, such as chronic lymphocytic leukemia, because most cells in these disorders are in the resting phase. Although subject to controversy, it is thought that quiescent lymphocytes contain DNA strand breaks that are continuously being formed and repaired. It is hypothesized that 2-CdA treatment of normal resting lymphocytes causes an increase in the amount of DNA strand breaks and thus leads to activation of poly (ADP-ribose) polymerase, which results in a lethal depletion of cellular NAD and ATP and consequential cell death. apoptosis. These results are very important because the 2-CdA physiological concentration used with patients in vivo is equivalent to 1.75 × 10 −7 M dose used in our in vitro assays, which CdA in previously treated patients. 28, 29 The response in cause a significant induction of apoptosis. Although the perpatients with B cell chronic lymphocytic leukemia resistant to centage of apoptosis is higher with the most elevated dose, fludarabine was also measured. [30] [31] [32] [33] this drug level is not suitable for using in vivo because the All these observations suggested that 2-CdA treatment of dose is limited by toxic effects in patients. These data suggest patients who had not been exposed to prior therapy might an interesting possibility in the 2-CdA treatment of previously result in higher response rates. 34, 35 In the first report to docuuntreated patients by chronic lymphocytic leukemia B cell ment the response rates of 2-CdA in patients with previously apoptosis induction. Flow cytometric analysis of apoptotic untreated CLL, the response rate seen is nearly double that cells is a rapid and simple method that may be a reliable obtained in previously treated patients. 36 All data use the same indicator of the effectiveness of 2-chlorodeoxyadenosine response criteria as recommended by the NCI. 37 patients' in vivo treatment. The purine nucleoside analogue mechanisms of action are
